These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16023504)

  • 41. Impact of metabolism on the safety of estrogen therapy.
    Prokai-Tatrai K; Prokai L
    Ann N Y Acad Sci; 2005 Jun; 1052():243-57. PubMed ID: 16024767
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-potency oestrogen and risk of endometrial cancer: a case-control study.
    Weiderpass E; Baron JA; Adami HO; Magnusson C; Lindgren A; Bergström R; Correia N; Persson I
    Lancet; 1999 May; 353(9167):1824-8. PubMed ID: 10359406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tamoxifen and endometrial cancer.
    Thylan S
    J Reprod Med; 1996 Nov; 41(11):830-1. PubMed ID: 8951133
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical inquiries. What is the best diagnostic approach to postmenopausal vaginal bleeding in women taking hormone replacement therapy?
    Kerns JW; Mabry S; Lopez R
    J Fam Pract; 2001 Oct; 50(10):843-4. PubMed ID: 11674884
    [No Abstract]   [Full Text] [Related]  

  • 45. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.
    Bjarnason NH
    Dan Med Bull; 2005 May; 52(2):64-81. PubMed ID: 16009050
    [No Abstract]   [Full Text] [Related]  

  • 46. Quantification of apoptotic phenomenon on endometrial biopsies in postmenopausal patients under hormonal replacement therapy (HRT).
    Terzea D; Iosif C; Vasilescu F; Andrei F; Dobrea C; Nicolae A; Georgescu A; Mircea F; Ceauşu M; Vişan A; Mihai M; Ardeleanu C
    Rom J Morphol Embryol; 2007; 48(2):107-11. PubMed ID: 17641796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship of hormone use to cancer risk.
    Bernstein L; Ross RK; Henderson BE
    J Natl Cancer Inst Monogr; 1992; (12):137-47. PubMed ID: 1616798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008.
    Fournier A; Dossus L; Mesrine S; Vilier A; Boutron-Ruault MC; Clavel-Chapelon F; Chabbert-Buffet N
    Am J Epidemiol; 2014 Sep; 180(5):508-17. PubMed ID: 25008104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France].
    Jamin C; Bourg F; Legeai J; Senoussi S
    Gynecol Obstet Fertil; 2006 Mar; 34(3):224-32. PubMed ID: 16513401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of ovarian and uterine cancers with postmenopausal hormonal treatments.
    Neves-E-Castro M
    Clin Obstet Gynecol; 2008 Sep; 51(3):607-17. PubMed ID: 18677154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hormone replacement therapy and malignancy.
    Fitzgerald CT; Elstein M; Mansel RE
    Br J Obstet Gynaecol; 1993 May; 100(5):408-10. PubMed ID: 8518237
    [No Abstract]   [Full Text] [Related]  

  • 52. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. The Scandinavian LongCycle Study Group.
    Cerin A; Heldaas K; Moeller B
    N Engl J Med; 1996 Mar; 334(10):668-9. PubMed ID: 8592546
    [No Abstract]   [Full Text] [Related]  

  • 53. Individualising hormone replacement therapy.
    Attilakos G; Wardle PG
    Practitioner; 2002 May; 246(1634):295-8, 302, 305 passim. PubMed ID: 12043347
    [No Abstract]   [Full Text] [Related]  

  • 54. Low-dose hormone therapy in postmenopausal women in China.
    Zang H; Shi H; Speroff L
    Climacteric; 2010 Dec; 13(6):544-52. PubMed ID: 19938946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT).
    Sourander L; Rajala T; Räihä I; Mäkinen J; Erkkola R; Helenius H
    Lancet; 1998 Dec 19-26; 352(9145):1965-9. PubMed ID: 9872245
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three cases of endometrial cancer associated with "bioidentical" hormone replacement therapy.
    Eden JA; Hacker NF; Fortune M
    Med J Aust; 2007 Aug; 187(4):244-5. PubMed ID: 17708728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endometrial hyperplasia and adenocarcinoma during tibolone (Livial) therapy.
    von Dadelszen P; Gillmer MD; Gray MD; McEwan HP; Pyper RJ; Rollason TP; Wright A
    Br J Obstet Gynaecol; 1994 Feb; 101(2):158-61. PubMed ID: 8305393
    [No Abstract]   [Full Text] [Related]  

  • 58. Hormone replacement therapy and cancer.
    Mack TM
    Baillieres Clin Endocrinol Metab; 1993 Jan; 7(1):113-49. PubMed ID: 8435049
    [No Abstract]   [Full Text] [Related]  

  • 59. Monitoring endometrial thickness during estrogen replacement therapy with vaginosonography.
    Meuwissen JH; van Langen H
    Radiology; 1992 Apr; 183(1):284. PubMed ID: 1549688
    [No Abstract]   [Full Text] [Related]  

  • 60. Hormone replacement therapy and surveillance considerations.
    Brood-van Zanten MM; Barentsen R; van der Mooren MJ
    Maturitas; 2002 Aug; 43 Suppl 1():S57-67. PubMed ID: 12361889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.